Suboptimal Clinical Response to Anti-tumor Necrosis Factor alpha (TNFα) Antibody Therapy in a Patient with Severe Rheumatoid Arthritis and Lymphadenopathy: CASE REPORT

By Saeki Yukihiko   Ohshima Shiro   Mima Toru   Sasai Mitsuko   Nishioka Katsuhiro   Shimizu Masatoshi   Suemura Masaki   McCloskey Richard   Kishimoto Tadamitsu  

Scandinavian Journal of Rheumatology, Vol. 27, Iss. 4, 1998-08 ,pp. : 303-305

Informa Healthcare

Access to resources Recommend Favorite

Is polymyositis or dermatomyositis in patients with rheumatoid arthritis induced or unveiled by anti-tumor necrosis factor treatment?

By Nagashima Takao   Minota Seiji  

Clinical Rheumatology, Vol. 29, Iss. 7, 2010-07 ,pp. : 819-820

Springer Publishing Company

Access to resources Recommend Favorite

Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor α-neutralizing antibody

By Mori Shunsuke   Imamura Fumiya   Kiyofuji Chikage   Sugimoto Mineharu  

Modern Rheumatology, Vol. 16, Iss. 4, 2006-08 ,pp. : 251-255

Springer Publishing Company

Access to resources Recommend Favorite

Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α

By Onishi Sachiko   Yoshio Taku   Nagashima Takao   Minota Seiji  

Modern Rheumatology, Vol. 20, Iss. 5, 2010-10 ,pp. : 528-530

Springer Publishing Company

Access to resources Recommend Favorite

Anti-Tumor Necrosis Factor-amp;#945; Therapy in Undifferentiated Spondyloarthritis (USpA)

By  

Current Rheumatology Reviews, Vol. 5, Iss. 3, 2009-08 ,pp. : 174-176

Bentham Science Publishers

Access to resources Recommend Favorite